Piper Sandler initiated coverage of Day One Biopharmaceuticals (DAWN) with an Overweight rating and $25 price target Piper thinks the stock move following the first two 2025 earnings reports is overdone and that these early decelerations of Ojemda are artifacts of a unique cancer indication wherein the prescribing physicians are risk-averse and slow to adopt novel therapies, the analyst tells investors in a research note. The firm continues to believe the clinical data will support strong penetration longer term.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals initiated with an Overweight at Piper Sandler
- Promising Growth and Stability Drive Buy Rating for Day One Biopharmaceuticals
- Day One Biopharma’s Earnings Call Highlights Growth and Strategy
- Promising Growth and Strategic Innovation Drive Buy Rating for Day One Biopharmaceuticals
- Buy Rating for Day One Biopharmaceuticals Amid Promising Future Catalysts Despite Current Challenges